Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Remote Electrical Neuromodulation for the Acute Treatment of Chronic Migraine
Headache
Headache Posters (7:00 AM-5:00 PM)
030

REN (Nerivio®, Theranica Bio-Electronics LTD., Israel) is an acute treatment for migraine. Results from several studies in patients with episodic migraine suggest that REN is an effective and safe acute treatment of migraine. In addition, a recent pilot study provided initial support that REN is effective in patients with chronic migraine, but additional data is needed to establish the effectiveness of REN in this population.

This study aimed to assess the safety and effectiveness of remote electrical neuromodulation (REN) in people with chronic migraine.

In this open-label, single-arm study, patients with chronic migraine treated their headaches with the device for 4 weeks following a 4-week run-in phase. Pain levels, associated symptoms and functional disability were recorded at treatment initiation, 2 hours after the treatment and 24 hours after the treatment.

One hundred and twenty-six subjects were enrolled into the study, of which 91 subjects had an evaluable treatment with REN. Pain relief and pain disappearance at 2 hours were achieved by 59.3% (54/91) and 20.9% (19/91) of subjects, respectively. Sustained pain relief at 24 hours was observed in 73.3% (33/45) of subjects. The findings of the study show that REN has a favorable effect on nausea, photophobia, and phonophobia, and improves functional ability. One device-related adverse event was reported.

REN treatments results in the relief of migraine headaches and associated symptoms, thus, offering a drug-free acute treatment option for people with chronic migraine.

Authors/Disclosures
Brian Grosberg, MD (Hartford HealthCare Headache Center)
PRESENTER
Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma pharmaceuticals. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Theranica . Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Grosberg has stock in Theranica. The institution of Dr. Grosberg has received research support from Theranica. The institution of Dr. Grosberg has received research support from Amgen. The institution of Dr. Grosberg has received research support from Abbvie. The institution of Dr. Grosberg has received research support from Eli Lilly. The institution of Dr. Grosberg has received research support from Teva. The institution of Dr. Grosberg has received research support from Neurolief. Dr. Grosberg has received publishing royalties from a publication relating to health care.
Tamar Lin (Theranica Bio-Electronics) Tamar Lin has received personal compensation for serving as an employee of Theranica Bio-Electronics.
Maya Vizel (Theranica Bio-Electronics) Maya Vizel has received personal compensation for serving as an employee of Theranica Bio-Electronics.
Jack D. Schim, MD, FAAN Dr. Schim has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aeon, Abbvie, Amgen, Biohaven, electroCore, Impel, Lilly, Lundbeck, Novartis, Promius, Revance, Teva, Upsher-Smith. Dr. Schim has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Promius, Teva, Theranica, Upsher-Smith.